Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 3
2019 5
2020 2
2021 2
2022 4
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Improving olaparib exposure to optimize adverse effects management.
Sterlé M, Puszkiel A, Burlot C, Pereira E, Bellesoeur A, De Percin S, Beinse G, Fumet JD, Favier L, Niogret J, Blanchet B, Royer B, Bengrine-Lefevre L, Schmitt A. Sterlé M, et al. Among authors: puszkiel a. Ther Adv Med Oncol. 2024 Apr 24;16:17588359241248328. doi: 10.1177/17588359241248328. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38665845 Free PMC article.
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
Puszkiel A, Bianconi G, Pasquiers B, Balakirouchenane D, Arrondeau J, Boudou-Rouquette P, Bretagne MC, Salem JE, Declèves X, Vidal M, Kramkimel N, Guegan S, Aractingi S, Huillard O, Alexandre J, Wislez M, Goldwasser F, Blanchet B. Puszkiel A, et al. Br J Cancer. 2024 Mar 26. doi: 10.1038/s41416-024-02659-x. Online ahead of print. Br J Cancer. 2024. PMID: 38532102
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
Blanchet B, Xu-Vuilard A, Jouinot A, Puisset F, Combarel D, Huillard O, Le Louedec F, Thomas F, Teixeira M, Flippot R, Mourey L, Albiges L, Pudlarz T, Joly C, Tournigand C, Chauvin J, Puszkiel A, Chatelut E, Decleves X, Vidal M, Goldwasser F, Oudard S, Medioni J, Vano YA. Blanchet B, et al. Among authors: puszkiel a. Br J Cancer. 2024 Apr;130(6):961-969. doi: 10.1038/s41416-024-02585-y. Epub 2024 Jan 25. Br J Cancer. 2024. PMID: 38272963
Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.
Balakirouchenane D, Seban R, Groussin L, Puszkiel A, Cottereau AS, Clerc J, Vidal M, Goldwasser F, Arrondeau J, Blanchet B, Huillard O. Balakirouchenane D, et al. Among authors: puszkiel a. Thyroid. 2023 Nov;33(11):1327-1338. doi: 10.1089/thy.2023.0228. Epub 2023 Oct 12. Thyroid. 2023. PMID: 37725566
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P, Fontaine J, Péron J, Maillet D, Tartas S, Bonnin N, Trillet-Lenoir V, Colomban O, Augu-Denechere D, Freyer G, Tod M. Puszkiel A, et al. Cancer Chemother Pharmacol. 2023 May;91(5):413-425. doi: 10.1007/s00280-023-04520-z. Epub 2023 Apr 3. Cancer Chemother Pharmacol. 2023. PMID: 37010549 Clinical Trial.
LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing's Syndrome.
Balakirouchenane D, Vasseur A, Bonnet-Serrano F, Choi M, Khoudour N, Puszkiel A, Groussin L, Vidal M, Declèves X, Bertherat J, Blanchet B. Balakirouchenane D, et al. Among authors: puszkiel a. J Pharm Biomed Anal. 2023 May 10;228:115316. doi: 10.1016/j.jpba.2023.115316. Epub 2023 Feb 25. J Pharm Biomed Anal. 2023. PMID: 36868030
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Varnier R, Puszkiel A, Tod M, Calattini S, Payen L, Lopez J, Guitton J, Schwiertz V, Fontaine J, Peron J, Maillet D, Tartas S, Bonnin N, Colomban O, Augu-Denechere D, Freyer G, You B. Varnier R, et al. Among authors: puszkiel a. Cancer Chemother Pharmacol. 2023 May;91(5):361-373. doi: 10.1007/s00280-023-04508-9. Epub 2023 Feb 25. Cancer Chemother Pharmacol. 2023. PMID: 36840749 Clinical Trial.
27 results